Millennium Pharmaceuticals achieved positive interim results from an international Phase III VISTA trial in patients with newly diagnosed multiple myeloma that showed Velcade therapy, melphalan and prednisone (VMP), demonstrated a statistically significant improvement in all efficacy measures, including time-to-disease progression, complete remission rate, progression-free survival and overall survival, compared to melphalan and prednisone (MP) alone. Based on the recommendation of an inde...